First tranche delivered, larger tranches en route: the same engine that just produced has visibly more already scheduled
The model's full reasoning — Q4 2016 call → NOWe need answer YES/NO. Need analyze transcript. Need identify engine of new business with first tranche landed and larger tranches in motion same engine, remainder larger, management treats as execution/timing. Need only transcript. Let's parse. Management discusses many programs. Need find one where concrete portion delivered in just-reported period (Q4/full year 2016) and further portions already committed/scheduled/ramping, larger ahead. Candidates: - Captisol: record sampling, new customers, but 2016 sales lower than expected, 2017 flat. Not first tranche landed? Existing business. - OmniAb: new partnerships, patent, but no specific first tranche? They mention OmniAb acquisition, annual access payments, milestones. Not concrete delivery? - Evomela: launched 2016, first year royalties, 20% royalty. Q3 growth, Q4 not reported. Expect solid measure new annual royalties in 2017 and beyond. Is this engine? First tranche landed: Evomela approved and launched in 2016, royalties earned. Larger tranches ahead? Spectrum not reported Q4, but product ramping? Management expects contribute solid measure. But is continuation "already secured or in motion"? Product launched, commercial sales ramping. But management doesn't explicitly say larger share ahead? They say "solid measure of new annual royalties in 2017 and beyond" - not necessarily larger than recognized. Also no committed volumes. - Promacta: existing product, growth 37%, expected >$1B, royalties tier. First tranche? Q4 sales $178M, full year $635M. Larger ahead? Analysts expect continued growth, eventually >$1B. But this is routine existing product, not new engine? Management treats as important. But "first tranche" not new; already substantial. - Kyprolis: similar. - Baxdela: PDUFA June 2017, not yet approved, no delivery. - Sparsentan: data, regulatory path, no delivery. - Verubecestat: failed, no. - Viking: Phase 2 readouts, no delivery. - Aldeyra: plans, no. - VX-970 licensed to Merck KGaA: Captisol-enabled, but no delivery? Vertex licensed rights to VX-970 to Merck KGaA. Ligand has relationship. Not first tranche. - New OmniAb partnership with Ono: annual access payments on each anniversary, milestones. Is first tranche landed? They announced partnership, entitled to annual access payments. But did they receive first payment? Not stated.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| ATAT | Atour Lifestyle Holdings Limited | Q1 2024 | 2024-05-23 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| ZLAB | Zai Lab Limited | Q4 2023 | 2024-02-28 | C |
| VMI | Valmont Industries, Inc. | Q4 2023 | 2024-02-22 | C |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| CLNE | Clean Energy Fuels Corp. | Q2 2023 | 2023-08-09 | C+ |
| LUCD | Lucid Diagnostics Inc. | Q1 2023 | 2023-05-16 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ARE | Alexandria Real Estate Equities, Inc. | Q4 2022 | 2023-01-31 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CDMO | Avid Bioservices, Inc. | Q3 2022 | 2022-03-08 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| FEIM | Frequency Electronics, Inc. | Q1 2019 | 2018-09-13 | B+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MGA | Magna International Inc. | Q1 2018 | 2018-05-10 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| HR | Healthcare Realty Trust Incorporated | Q1 2017 | 2017-05-08 | A |
| BDN | Brandywine Realty Trust | Q1 2017 | 2017-04-21 | C+ |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| MTRX | Matrix Service Company | Q3 2016 | 2016-05-05 | D |
| CLF | Cleveland-Cliffs Inc. | Q1 2016 | 2016-04-29 | F |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
CDMO · Q3 2022 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: NO The transcript describes the first phase of the Myford expansion as now operational and scheduling client projects, with management noting they are already utilizing the new space and that an extra $5 million is arguably in backlog attributable to it.
LINC · Q1 2024 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: YES The transcript identifies the new-campus expansion strategy as the engine. East Point opened in Q1 with 29 starts and $90k revenue (first tranche, concrete and delivered).
LTRX · Q3 2024 → YESThe question is about whether management describes one identifiable engine of new business that meets two criteria: a first tranche has actually landed in the just-reported period, and larger tranches...